Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann–Pick disease type C1 mice

This work highlights the importance of CNS transduction for treatment of neurological diseases, a finding with significant clinical implications considering the long-lasting effects of gene therapy. Niemann–Pick C1 disease (NPC1) is a rare, fatal neurodegenerative disease caused by mutations in NPC1, which encodes the lysosomal cholesterol transport protein NPC1. Disease pathology involves lysosomal accumulation of cholesterol and lipids, leading to neurological and visceral complications. Targeting the central nervous system (CNS) from systemic circulation complicates treatment of neurological diseases with gene transfer techniques. Selected and engineered capsids, for example, adeno-associated virus (AAV)-PHP.B facilitate peripheral-to-CNS transfer and hence greater CNS transduction than parental predecessors. We report that systemic delivery to Npc1m1N/m1N mice using an AAV-PHP.B vector ubiquitously expressing NPC1 led to greater disease amelioration than an otherwise identical AAV9 vector. In addition, viral copy number and biodistribution of GFP-expressing reporters showed that AAV-PHP.B achieved more efficient, albeit variable, CNS transduction than AAV9 in Npc1m1N/m1N mice. This variability was associated with segregation of two alleles of the putative AAV-PHP.B receptor Ly6a in Npc1m1N/m1N mice. Our data suggest that robust improvements in NPC1 disease phenotypes occur even with modest CNS transduction and that improved neurotrophic capsids have the potential for superior NPC1 AAV gene therapy vectors.

[1]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[2]  M. Kumar,et al.  Global CNS correction in a large brain model of human alpha-mannosidosis by intravascular gene therapy. , 2020, Brain : a journal of neurology.

[3]  N. Kollu,et al.  Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea. , 2020, Human gene therapy.

[4]  D. Corey,et al.  Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea , 2020, Hearing Research.

[5]  R. Samulski,et al.  Engineering adeno-associated virus vectors for gene therapy , 2020, Nature Reviews Genetics.

[6]  Yueh-Chiang Hu,et al.  Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-/- mice. , 2020, Human molecular genetics.

[7]  D. Watkins-Chow,et al.  Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1 , 2020, Disease Models & Mechanisms.

[8]  Zhi-Yao He,et al.  The approved gene therapy drugs worldwide: from 1998 to 2019. , 2019, Biotechnology advances.

[9]  O. King,et al.  Ly6a differential expression in BBB is responsible for strain specific CNS transduction profile of AAV-PHP.B. , 2019, Human gene therapy.

[10]  William A Liguore,et al.  AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  E. Hudry,et al.  Selection of an Efficient AAV Vector for Robust CNS Transgene Expression , 2019, Molecular therapy. Methods & clinical development.

[12]  Benjamin E. Deverman,et al.  Whole brain delivery of an instability-prone Mecp2 transgene improves behavioral and molecular pathological defects in mouse models of Rett syndrome , 2019, bioRxiv.

[13]  Bruce J. Melancon,et al.  2-Hydroxypropyl-β-cyclodextrin is the active component in a triple combination formulation for treatment of Niemann-Pick C1 disease. , 2019, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[14]  Elaheh Sadat Hosseini,et al.  Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders , 2019, Front. Genet..

[15]  J. Mendell,et al.  Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. , 2019, Pediatric neurology.

[16]  W. Stanford,et al.  The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  E. Hudry,et al.  Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality , 2019, Neuron.

[18]  Christine L. Boutros,et al.  Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids , 2019, bioRxiv.

[19]  S. Pfeffer,et al.  NPC intracellular cholesterol transporter 1 (NPC1)-mediated cholesterol export from lysosomes , 2019, The Journal of Biological Chemistry.

[20]  Fengqin Gao,et al.  Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid α-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease , 2019, Molecular therapy. Methods & clinical development.

[21]  J. Mendell,et al.  Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy , 2018, Pediatric pulmonology.

[22]  R. Crystal,et al.  Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2 , 2018, Experimental Neurology.

[23]  B. Hyman,et al.  Efficient Gene Transfer to the Central Nervous System by Single-Stranded Anc80L65 , 2018, Molecular therapy. Methods & clinical development.

[24]  E. Henckaerts,et al.  AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann–Pick type C1 disease , 2018, Human molecular genetics.

[25]  L. Shihabuddin,et al.  Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain , 2018, Gene Therapy.

[26]  E. Bowman,et al.  HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients. , 2018, Lung cancer.

[27]  S. Gray,et al.  Recent progress and considerations for AAV gene therapies targeting the central nervous system , 2018, Journal of neurodevelopmental disorders.

[28]  David J. Anderson,et al.  The Neuropeptide Tac2 Controls a Distributed Brain State Induced by Chronic Social Isolation Stress , 2018, Cell.

[29]  A. Pshezhetsky,et al.  A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency , 2018, Brain : a journal of neurology.

[30]  M. Patterson,et al.  Consensus clinical management guidelines for Niemann-Pick disease type C , 2018, Orphanet Journal of Rare Diseases.

[31]  T. Flotte,et al.  A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates , 2018, Molecular therapy. Methods & clinical development.

[32]  Qiang Wang,et al.  The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  HindererChristian,et al.  Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN , 2018 .

[34]  Yukihiro Okada,et al.  Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain , 2018, Neuroscience Letters.

[35]  L. Leocani,et al.  AAV-PHP.B-Mediated Global-Scale Expression in the Mouse Nervous System Enables GBA1 Gene Therapy for Wide Protection from Synucleinopathy. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Kimberly A. Walters,et al.  Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1–2 trial , 2017, The Lancet.

[37]  S. Brimijoin,et al.  Therapeutic Delivery of Butyrylcholinesterase by Brain-Wide Viral Gene Transfer to Mice , 2017, Molecules.

[38]  Jie Luo,et al.  AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease[S] , 2017, Journal of Lipid Research.

[39]  M. Mehler,et al.  Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease , 2016, Neurobiology of Disease.

[40]  L. Pereira de Almeida,et al.  Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Benjamin E. Deverman,et al.  Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B , 2016, Front. Mol. Neurosci..

[42]  W. Pavan,et al.  Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1 , 2016, Human molecular genetics.

[43]  K. Haldar,et al.  Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model , 2016, Science Translational Medicine.

[44]  Sripriya Ravindra Kumar,et al.  Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain , 2015, Nature Biotechnology.

[45]  F. Maxfield,et al.  A Murine Niemann-Pick C1 I1061T Knock-In Model Recapitulates the Pathological Features of the Most Prevalent Human Disease Allele , 2015, The Journal of Neuroscience.

[46]  C. Vite,et al.  Cholesterol homeostatic responses provide biomarkers for monitoring treatment for the neurodegenerative disease Niemann-Pick C1 (NPC1). , 2014, Human molecular genetics.

[47]  C. Vite,et al.  Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling , 2013, Journal of Lipid Research.

[48]  M. Patterson,et al.  Disease and patient characteristics in NP-C patients: findings from an international disease registry , 2013, Orphanet Journal of Rare Diseases.

[49]  R. Samulski,et al.  Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates , 2012, Gene Therapy.

[50]  K. Foust,et al.  Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. , 2012, Human gene therapy.

[51]  V. Shakkottai,et al.  Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration. , 2011, Human molecular genetics.

[52]  J. Mendell,et al.  Systemic Gene Delivery in Large Species for Targeting Spinal Cord, Brain, and Peripheral Tissues for Pediatric Disorders , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  D. Spray,et al.  Acquired infection with Toxoplasma gondii in adult mice results in sensorimotor deficits but normal cognitive behavior despite widespread brain pathology. , 2010, Microbes and infection.

[54]  G. Garden,et al.  A Simple Composite Phenotype Scoring System for Evaluating Mouse Models of Cerebellar Ataxia , 2010, Journal of visualized experiments : JoVE.

[55]  H. Paulson,et al.  Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. , 2010, Human molecular genetics.

[56]  J. Goldstein,et al.  NPC2 facilitates bidirectional transfer of cholesterol between NPC1 and lipid bilayers, a step in cholesterol egress from lysosomes , 2008, Proceedings of the National Academy of Sciences.

[57]  David Jelínek,et al.  Characterization of liver disease and lipid metabolism in the Niemann‐Pick C1 mouse , 2007, Journal of cellular biochemistry.

[58]  M. Raíces,et al.  Correction: Uncoupling of Longevity and Telomere Length in C. elegans , 2005, PLoS Genetics.

[59]  H. Ninomiya,et al.  [Niemann-Pick disease type C]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.

[60]  R. Wattiaux,et al.  Identification of HE1 as the second gene of Niemann-Pick C disease. , 2000, Science.

[61]  K. G. Coleman,et al.  Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. , 1997, Science.

[62]  S. Sherlock,et al.  Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. , 1993, The Journal of pediatrics.

[63]  R. Brady,et al.  Type C Niemann-Pick disease: a murine model of the lysosomal cholesterol lipidosis accumulates sphingosine and sphinganine in liver. , 1992, Biochimica et biophysica acta.

[64]  H. Shio,et al.  Lysosome lipid storage disorder in NCTR-BALB/c mice. I. Description of the disease and genetics. , 1982, The American journal of pathology.

[65]  R. Brady,et al.  A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase. , 1980, Biochimica et biophysica acta.

[66]  S. Cologna,et al.  Insights into the Molecular Mechanisms of Cholesterol Binding to the NPC1 and NPC2 Proteins. , 2019, Advances in experimental medicine and biology.

[67]  Michael J. Castle,et al.  Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. , 2016, Methods in molecular biology.

[68]  Philippe Latour,et al.  Laboratory diagnosis of Niemann-Pick disease type C: the filipin staining test. , 2015, Methods in cell biology.

[69]  M. Vanier.  Niemann-Pick diseases. , 2013, Handbook of clinical neurology.

[70]  M. D. Morris,et al.  Tissue cholesterol storage disorder in balb/c mice. Abstr. , 1977 .